Sage Journals: Discover world-class research

Abstract

Bivalirudin and glycoprotein IIb/IIIa antagonists are commonly used during percutaneous coronary interventions (PCI). The Pharmacy Department of Charlton Memorial Hospital implemented a dosing flow sheet that is operated by the Cardiac Catheter Lab nursing staff. The computer-oriented program utilizes the Microsoft Excel spreadsheet program. The computer spreadsheet calculates an estimated creatinine clearance (CrCl) rate and inserts proper renal adjusted dosages of both bivalirudin and glycoprotein IIb/IIIa antagonists into a printed flow sheet. The computer program is encoded to follow specific medication regimens for patients whether or not they are on dialysis. Institutions can develop medication dosing flow-sheet forms utilizing the spreadsheet concept.

Keywords

Computer spreadsheet Excel bivalirudin eptifibatide abciximab

Get full access to this article

View all access options for this article.

References

Zolnierz

Hospital pharmacy-based, computer-generated Tikosyn (dofetilide) physician order protocol. Hosp Pharm. 2003; 38: 659–661.

Freeland

, Worthy

, Zolnierz

Initiation and monitoring of class III antiarrhythmic agents. J Cardiovasc Electrophysiol. 2003; 14: S291–S295.

Saxer

S.B.

, Smith

B.S.

, Gandhi

P.J.

Recommended and actual lepirudin doses in patients with renal insufficiency. Am J Health Syst Pharm. 2003; 60: 2588–2593.

Lincoff

A.M.

, Bittl

J.A.

, Harrington

R.A.

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003; 289(7): 853–863.

Bittl

J.A.

, Chaitman

B.R.

, Kimball

, Topol

E.J.

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the bivalirudin angioplasty study. Am Heart J. 2001; 142(6): 952–959.

Angiomax – Use in patients with renal impairment. The Medicines Company. Available at: www.angiomax.com/. Accessed on July 28, 2005.

Angiomax [package insert]. Parsippany, NJ: The Medicines Company; 2002.

Mehta

, Yebara

S.M.

, Ibrahim

Cedar's Medical Center experience: early ambulation post PCI with the use of direct thrombin inhibitor, bivalirudin. Cath Lab Digest. 2004; 12: 24–27.

Integrilin [package insert]. Emeryville, CA: Millennium Pharmaceuticals; 1998.

10.

Reddan

D.N.

, O'Shea

J.C.

, Sarembock

I.J.

Treatment effects of eptifibatide in planed coronary stent implantation in patients with chronic kidney disease. (ESPRIT Trial). Am J Cardiol. 2003; 91(1): 17–21.

11.

Rasty

, Borzak

, Tisdale

Bleeding associated with eptifibatide target-inghigher risk patients with acute coronary syndromes: incidence and multivariate risk factors. J Clin Pharmacol. 2002; 42: 1366–1373.

12.

The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993; 329: 673–682.

13.

American College of Cardiology National Cardiovascular Data Registry. Cardiac Catheterization Module 3.03. Available at: www.accncdr.com/webNCDR/NCDRDocuments/datadictdefsonlyv30.pdf. Accessed on September 7, 2005.

Cardiac Catheter Laboratory Based Computer Generated Bivalirudin/Glycoprotein IIb/IIIa Flow Sheet

Abstract

Keywords

Get full access to this article

References